Publications by authors named "Melissa Aldinger"

Claim this Profile
S
Safety, Tolerability, Pharmacokinetics, and Viral Pharmacodynamics of the Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection in Participants with Early, Mild-to-Moderate COVID-19: A Randomized Clinical Trial.
Anil Gupta, Maria Teresa Perez-Rodríguez, Yaneicy Gonzalez-Rojas, Moti Ramgopal, Almena Free, Melissa Aldinger

Drugs R D· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lecanemab Treatment in a Specialty Memory Clinic.
Madeline Paczynski, Anna Hofmann, Zachary Posey, Maren Gregersen, Michelle Rudman, Melissa Aldinger

JAMA Neurol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites.
Asma El-Zailik, Jennifer Sager, Yasmin Sánchez-Pearson, Sergio Parra, Jennifer Moore, Melissa Aldinger

Clin Pharmacol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study.
Sambhavi Subramanian, Gretja Schnell, Julia di Iulio, Anil K Gupta, Adrienne E Shapiro, Melissa Aldinger

Future Virol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19.
Sacha Satram, Parima Ghafoori, Carolina M Reyes, Tom J H Keeley, Helen J Birch, Melissa Aldinger

J Patient Rep Outcomes· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial.
Jaynier Moya, Marisol Temech, Sergio Parra, Erick Juarez, Reinaldo Hernandez-Loy, Melissa Aldinger

Open Forum Infect Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and exposure-response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19.
Jennifer E Sager, Asma El-Zailik, Julie Passarell, Stefan Roepcke, Xiaobin Li, Melissa Aldinger

CPT Pharmacometrics Syst Pharmacol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody therapy reverses biological signatures of COVID-19 progression.
M Cyrus Maher, Leah B Soriaga, Anil Gupta, Yi-Pei Chen, Julia di Iulio, Melissa Aldinger

Cell Rep Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, Manuel Crespo Casal, Jaynier Moya, Melissa Aldinger

JAMA· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, Manuel Crespo Casal, Jaynier Moya, Melissa Aldinger

N Engl J Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis